Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will report first-quarter 2026 financial results on Thursday, May 7, 2026, after the U.S. market close.

Rhea-AI Summary

Nektar Therapeutics (Nasdaq: NKTR) will report first-quarter 2026 financial results on Thursday, May 7, 2026, after the U.S. market close. Howard Robin, president and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT to review results.

The live audio-only webcast and press release will be available via the company’s investor website. The web broadcast replay will remain available through June 7, 2026. Registrants will receive dial-in details and a PIN; pre-registration is required for call access.

Argus Apr 29 session

-0.73% close to close Open Argus

Details

News Market Reaction – NKTR

On Apr 29, the first trading day after this news, NKTR closed 0.73% below the previous close.

Data tracked by StockTitan Argus for the Apr 29 session.

Market Context

This announcement schedules first‑quarter 2026 results for May 7, 2026 with a conference call at 5:0...

Analysis

This announcement schedules first‑quarter 2026 results for May 7, 2026 with a conference call at 5:00 p.m. ET and webcast replay through June 7, 2026. It follows a busy period that included equity offerings, a liquidity update citing $741.7 million in cash and securities, and positive Phase 2b data. Investors may focus on how upcoming results interact with this strengthened balance sheet and recent clinical progress.

Key Figures

Public offering gross proceeds: $373.8 million Upsized offering size: $325 million Proposed offering size: $250,000,000 +5 more

Public offering gross proceeds

$373.8 million

Closed underwritten offering on Apr 23, 2026

Upsized offering size

$325 million

Priced public offering on Apr 21, 2026

Proposed offering size

$250,000,000

Proposed public offering on Apr 20, 2026

Cash and marketable securities

$741.7 million

Preliminary liquidity as of Apr 1, 2026

Shares outstanding

29,679,647 shares

Common shares outstanding as of Apr 6, 2026

Short interest

10.81%

Reported short position in NKTR shares

Shares in Apr 23 offering

3,532,609 shares

Common stock offered at $92.00 per share

ATM shares sold

1,532,850 shares

ATM program completed at $71.76 average price

Previous Earnings date Reports

1 past event · Latest: Feb 26

Same Type 1 event

1. Feb 26

   Earnings date set

   24h Move

   +4.7%

   Scheduled Q4 and full‑year 2025 results with post‑close conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through June 7, 2026.

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

For Investors:

Vivian Wu
628-895-0661
VWu@nektar.com

Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com 

For Media:

Susan Roberts
LifeSci Communications
202-779-0929
sroberts@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-first-quarter-on-thursday-may-7-2026-after-close-of-us-based-financial-markets-302756324.html

SOURCE Nektar Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Nektar (NKTR) release its Q1 2026 earnings and what time is the conference call?

Nektar will release Q1 2026 results on May 7, 2026 after U.S. market close. According to Nektar, the company will host a conference call beginning at 5:00 p.m. ET / 2:00 p.m. PT that day to review results.

How can investors access the Nektar (NKTR) May 7, 2026 earnings call and webcast?

Investors can access the live audio-only webcast via Nektar’s investor site and should pre-register for the call. According to Nektar, registrants will receive dial-in information and a PIN to join the live conference call.

Will the Nektar (NKTR) earnings call be available for replay and until when?

Yes. According to Nektar, the web broadcast replay of the May 7, 2026 earnings call will be available through June 7, 2026. The replay can be accessed via the company’s investor website during that period.

Who will present Nektar's Q1 2026 results on the May 7 call and what is their role?

Howard Robin, president and chief executive officer, will host the May 7, 2026 conference call. According to Nektar, he will review the company’s first-quarter financial results during the live audio-only webcast.

Where is the official place to find the Nektar (NKTR) press release and earnings call link?

The official press release and live-call link will be posted on Nektar’s investor website homepage and Investors section. According to Nektar, all materials and the webcast access link will be available at https://ir.nektar.com/.

Do I need to register in advance for the Nektar (NKTR) earnings call and what happens after registration?

Yes, pre-registration is required to access the live call. According to Nektar, after registering you will receive dial-in information and a PIN that allow participation in the live conference call and webcast.